-
Something wrong with this record ?
Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma
I. Trávníček, J. Branžovský, K. Kalusová, O. Hes, L. Holubec, KB. Pele, T. Ürge, M. Hora,
Language English Country Greece
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12010
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
Free Medical Journals
from 2004 to 2 years ago
Open Access Digital Library
from 2004-01-01
PubMed
26408740
Knihovny.cz E-resources
- MeSH
- Tissue Array Analysis methods MeSH
- Adult MeSH
- Immunoenzyme Techniques MeSH
- Indoles therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy mortality secondary MeSH
- Kidney metabolism pathology MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphatic Metastasis MeSH
- Survival Rate MeSH
- Biomarkers, Tumor metabolism MeSH
- Kidney Neoplasms drug therapy mortality pathology MeSH
- Follow-Up Studies MeSH
- Prognosis MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyrroles therapeutic use MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Case-Control Studies MeSH
- Neoplasm Grading MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
AIM: To identify tissue biomarkers that are predictive of the therapeutic effect of sunitinib in treatment of metastatic clear cell renal cell carcinoma (mCRCC). MATERIALS AND METHODS: Our study included 39 patients with mCRCC treated with sunitinib. Patients were stratified into two groups based on their response to sunitinib treatment: non-responders (progression), and responders (stable disease, regression). The effect of treatment was measured by comparing imaging studies before the initiation treatment with those performed at between 3rd and 7th months of treatment, depending on the patient. Histological samples of tumor tissue and healthy renal parenchyma, acquired during surgery of the primary tumor, were examined with immunohistochemistry to detect tissue targets involved in the signaling pathways of tumor growth and neoangiogenesis. We selected mammalian target of rapamycine, p53, vascular endothelial growth factor, hypoxia-inducible factor 1 and 2 and carbonic anhydrase IX. We compared the average levels of biomarker expression in both, tumor tissue, as well as in healthy renal parenchyma. Results were evaluated using the Student's t-test. RESULTS: For responders, statistically significant differences in marker expression in tumor tissue versus healthy parenchyma were found for mTOR (4%/16.7%; p=0.01031), p53 (4%/12.7%; p=0.042019), VEGF (62.7%/45%; p=0.019836) and CAIX (45%/15.33%; p=0.001624). A further significant difference was found in the frequency of high expression (more than 60%) between tumor tissue and healthy parenchyma in VEGF (65%/35%; p=0.026487) and CAIX (42%/8%; p=0.003328). CAIX was expressed at high levels in the tumor tissue in both evaluated groups. CONCLUSION: A significantly higher expression of VEGF in CRCC in comparison to healthy parenchyma can predict a better response to sunitinib.
Department of Oncology and Radiotherapy Faculty Hospital in Pilsen Pilsen Czech Republic
Department of Pathology Faculty Hospital in Pilsen Pilsen Czech Republic
Department of Urology Faculty Hospital in Pilsen Pilsen Czech Republic
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16009947
- 003
- CZ-PrNML
- 005
- 20241120101115.0
- 007
- ta
- 008
- 160408s2015 gr f 000 0|engg|
- 009
- AR
- 035 __
- $a (PubMed)26408740
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Trávníček, Ivan $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic travniceki@fnplzen.cz. $7 xx0227802
- 245 10
- $a Tissue Biomarkers in Predicting Response to Sunitinib Treatment of Metastatic Renal Cell Carcinoma / $c I. Trávníček, J. Branžovský, K. Kalusová, O. Hes, L. Holubec, KB. Pele, T. Ürge, M. Hora,
- 520 9_
- $a AIM: To identify tissue biomarkers that are predictive of the therapeutic effect of sunitinib in treatment of metastatic clear cell renal cell carcinoma (mCRCC). MATERIALS AND METHODS: Our study included 39 patients with mCRCC treated with sunitinib. Patients were stratified into two groups based on their response to sunitinib treatment: non-responders (progression), and responders (stable disease, regression). The effect of treatment was measured by comparing imaging studies before the initiation treatment with those performed at between 3rd and 7th months of treatment, depending on the patient. Histological samples of tumor tissue and healthy renal parenchyma, acquired during surgery of the primary tumor, were examined with immunohistochemistry to detect tissue targets involved in the signaling pathways of tumor growth and neoangiogenesis. We selected mammalian target of rapamycine, p53, vascular endothelial growth factor, hypoxia-inducible factor 1 and 2 and carbonic anhydrase IX. We compared the average levels of biomarker expression in both, tumor tissue, as well as in healthy renal parenchyma. Results were evaluated using the Student's t-test. RESULTS: For responders, statistically significant differences in marker expression in tumor tissue versus healthy parenchyma were found for mTOR (4%/16.7%; p=0.01031), p53 (4%/12.7%; p=0.042019), VEGF (62.7%/45%; p=0.019836) and CAIX (45%/15.33%; p=0.001624). A further significant difference was found in the frequency of high expression (more than 60%) between tumor tissue and healthy parenchyma in VEGF (65%/35%; p=0.026487) and CAIX (42%/8%; p=0.003328). CAIX was expressed at high levels in the tumor tissue in both evaluated groups. CONCLUSION: A significantly higher expression of VEGF in CRCC in comparison to healthy parenchyma can predict a better response to sunitinib.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protinádorové látky $x terapeutické užití $7 D000970
- 650 _2
- $a nádorové biomarkery $x metabolismus $7 D014408
- 650 _2
- $a karcinom z renálních buněk $x farmakoterapie $x mortalita $x sekundární $7 D002292
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunoenzymatické techniky $7 D007124
- 650 _2
- $a indoly $x terapeutické užití $7 D007211
- 650 _2
- $a ledviny $x metabolismus $x patologie $7 D007668
- 650 _2
- $a nádory ledvin $x farmakoterapie $x mortalita $x patologie $7 D007680
- 650 _2
- $a lymfatické metastázy $7 D008207
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a stupeň nádoru $7 D060787
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a pyrroly $x terapeutické užití $7 D011758
- 650 _2
- $a míra přežití $7 D015996
- 650 _2
- $a čipová analýza tkání $x metody $7 D046888
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Branžovský, Jindřich, $d 1987- $u Department of Pathology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $7 xx0324720
- 700 1_
- $a Procházková, Kristýna, $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $d 1982- $7 xx0227765
- 700 1_
- $a Hes, Ondřej, $u Department of Pathology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $d 1968- $7 jn20001103502
- 700 1_
- $a Holubec, Luboš, $d 1972- $7 xx0068645 $u Department of Oncology and Radiotherapy, Faculty Hospital in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Pele, Kevin Bauleth $u Department of Pathology, Faculty Hospital in Pilsen, Pilsen, Czech Republic.
- 700 1_
- $a Ürge, Tomáš $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $7 xx0092825
- 700 1_
- $a Hora, Milan, $u Department of Urology, Faculty Hospital in Pilsen, Pilsen, Czech Republic. $d 1967- $7 mzk2004258359
- 773 0_
- $w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 35, č. 10 (2015), s. 5661-5666
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26408740 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160408 $b ABA008
- 991 __
- $a 20241120101110 $b ABA008
- 999 __
- $a ok $b bmc $g 1113376 $s 934315
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 35 $c 10 $d 5661-5666 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
- GRA __
- $a NT12010 $p MZ0
- LZP __
- $a Pubmed-20160408